MOVEMENT DISORDERS

NeurologyLive's Movement Disorders Clinical Focus page focuses on the latest news and research across a variety of movement disorders, such as Parkinson disease, Tardive dyskinesia, Huntington disease, and tremors.

Insight from Eric Bastings, MD

Istradefylline Approved for Parkinson Add-On Therapy

After being approved in Japan in 2013, the selective adenosine A 2A receptor antagonist was given the OK as an add-on to levodopa/carbidopa treatment in adults with Parkinson disease.

Tic Suppression Ability Predicts Future Symptom Outcomes, Wearable-Detected Gait Changes Predict Parkinson Disease, Early MRI Scans Predict Relapse-Onset Multiple Sclerosis

Neurology News Network for the week ending August 3, 2019.

RimabotulinumtoxinB Approved for Chronic Sialorrhea

US WorldMeds rimabotulinumtoxinB injection showed significant decreases in sialorrhea symptoms with a single treatment as soon as the first week, lasting up to 3 months in clinical studies.

Parkinson DBS System Labels Approved For Use With Full-Body MRI

Boston Scientific’s Vercise Gevia deep brain stimulation system labels will allow for clinical use of stimulation during full-body MRI in patients with Parkinson disease, with an improved battery.

FDA Rules Out Prostate Cancer Risk With Parkinson Disease Therapy

The review is an update to a drug safety communication initially issued in 2010 after trial results suggested a possible increased risk for prostate cancer with use of entacapone.

Marisa McGinley, DO: Advantages of Outpatient Telemedicine in Neurology Subspecialties

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness

Noah Rosen, MD: Lessons Learned From the Father of Neurology

Previous Page Next Page

About NeurologyLive's Movement Disorders Clinical Focus page:

The NeurologyLive Movement Disorder Clinical Focus center provides a source of up-to-date clinical information, with articles covering updates from the robust pipeline of novel therapies, and the newest data from all phases of clinical trials and studies in the space. It also serves as a hub of information and news from the upcoming and ongoing conferences and annual meetings hosted by neurological societies and associations on the latest advances in Parkinson disease, Tardive dyskinesia, Huntington disease, and more.

This resource includes a wealth of interviews with movement disorder specialists, and moderated Peer Exchange discussions about the best practices and key methods for treating complex cases, utilizing the newest therapies, examining the issues and challenges of treatment options, and much more.